君圣泰医药-B(02511)发布年度业绩，股东应占亏损2.45亿元同比减少35.84%

智通财经03-27

智通财经APP讯，君圣泰医药-B(02511)发布截至2025年12月31日止年度业绩，该集团取得其他收入1900.7万元，同比减少72.04%;公司拥有人应占亏损2.45亿元，同比减少35.84%;每股亏损0.51元。公司的研发团队在CKM相关疾病方面拥有丰富的专业知识、深刻的理解及广泛的开发经验。公司进行的药物发现及临床活动包括：协调所有临床开发活动;设计临床研究的关键环节;设计及协调合格合约...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2622084061?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-27 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622084061","market":"us","top_or_hot":-1,"title":"君圣泰医药-B(02511)发布年度业绩，股东应占亏损2.45亿元 同比减少35.84%","media":"智通财经","content":"<div>\n<p>智通财经APP讯，君圣泰医药-B(02511)发布截至2025年12月31日止年度业绩，该集团取得其他收入1900.7万元，同比减少72.04%;公司拥有人应占亏损2.45亿元，同比减少35.84%;每股亏损0.51元。公司的研发团队在CKM相关疾病方面拥有丰富的专业知识、深刻的理解及广泛的开发经验。公司进行的药物发现及临床活动包括：协调所有临床开发活动;设计临床研究的关键环节;设计及协调合格合约...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1420567.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>君圣泰医药-B(02511)发布年度业绩，股东应占亏损2.45亿元 同比减少35.84%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n君圣泰医药-B(02511)发布年度业绩，股东应占亏损2.45亿元 同比减少35.84%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-27 18:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1420567.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，君圣泰医药-B(02511)发布截至2025年12月31日止年度业绩，该集团取得其他收入1900.7万元，同比减少72.04%;公司拥有人应占亏损2.45亿元，同比减少35.84%;每股亏损0.51元。公司的研发团队在CKM相关疾病方面拥有丰富的专业知识、深刻的理解及广泛的开发经验。公司进行的药物发现及临床活动包括：协调所有临床开发活动;设计临床研究的关键环节;设计及协调合格合约...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1420567.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02511","symbol_name":"君圣泰医药-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1420567.html","article_id":"2622084061","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622084061","pubTimestamp":1774606852,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，君圣泰医药-B 发布截至2025年12月31日止年度业绩，该集团取得其他收入1900.7万元，同比减少72.04%;公司拥有人应占亏损2.45亿元，同比减少35.84%;每股亏损0.51元。公司的研发团队在CKM相关疾病方面拥有丰富的专业知识、深刻的理解及广泛的开发经验。公司的研发团队由一组于药物开发方面具有多年经验的世界级科学家领导。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02511":"君圣泰医药-B","BK1161":"生物科技"},"translate_title":"Junshengtai Pharmaceutical-B (02511) released its annual results, with a loss attributable to shareholders of 245 million yuan, a year-on-year decrease of 35.84%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02511":1.5},"content_text":"智通财经APP讯，君圣泰医药-B(02511)发布截至2025年12月31日止年度业绩，该集团取得其他收入1900.7万元，同比减少72.04%;公司拥有人应占亏损2.45亿元，同比减少35.84%;每股亏损0.51元。公司的研发团队在CKM相关疾病方面拥有丰富的专业知识、深刻的理解及广泛的开发经验。公司进行的药物发现及临床活动包括：协调所有临床开发活动;设计临床研究的关键环节;设计及协调合格合约研究机构的甄选程序，以协助委聘临床机构并于临床研究开始后进行协调;监督临床研究;及监督于中国及其他司法权区开展的广泛监管外联及协调工作。公司的研发团队由一组于药物开发方面具有多年经验的世界级科学家领导。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622084061","isCrawlerRequest":true}

君圣泰医药-B(02511)发布年度业绩，股东应占亏损2.45亿元 同比减少35.84%

精彩评论

君圣泰医药-B(02511)发布年度业绩，股东应占亏损2.45亿元同比减少35.84%